The Diabetes wiREless Artificial Pancreas ConsortiuM (DREAM) was established by 3 diabetes centers in Slovenia, Germany and Israel. The DREAM goal is to reduce the risk of nocturnal hypoglycemia while improving nocturnal blood glucose control and reducing patient's burden of diabetes management by using the MD-Logic Artificial Pancreas. The MD-Logic is a wireless fully automated closed-loop system based on a fuzzy logic theory algorithm, a learning algorithm, a personalized system setting and alerts module.

Since October 2010, we have conducted in silico studies using the FDA approved UVA simulator (N=300 virtual patients) as well as 6 clinical studies which took place in Israel, Germany and Slovenia. Around 200 adults, adolescents and children with type 1 diabetes participated in the studies. The clinical studies included feasibility in hospital studies as well as prospective randomized controlled, multicenter multinational cross-over studies conducted in three settings : (i) in hospital, (ii) at a diabetes camp and (iii) 4-night study at patients’ homes. These studies consist of around 15,000 hours of closed-loop control and 1,000 nights at home with MD-Logic Artificial Pancreas treatment.

Studies results demonstrated the safety and efficacy of using the MD-Logic Artificial Pancreas for overnight glucose control. In all studies, the MD-Logic artificial pancreas system achieved significantly less hypoglycemia and tighter overnight glucose control compared to standard treatment (i.e. CSII or sensor augmented pump therapy).

The MD-Logic may safely integrate into lives of people with diabetes providing a potent tool to lower the rate of nocturnal hypoglycemia and improve overall glucose control. The DREAM consortium is now evaluating the MD-Logic system in a longer study period at patients’ homes.